Alphatec Holdings, Inc. (ATEC)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$7.80-5.80%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · ATEC
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
These results reinforce our confidence in our procedure-focused strategy and the clinical value of our ecosystem.
Stated in 2 of 3 supplied quarters. Management reported: “At the same time, we continued to see very strong demand for our procedural solutions, with hardware revenue growing 17%, case volumes growing approximately 20%, and new surgeon adoption increasing 25%.” ““During the quarter, we saw 20 percent case volume growth, continued to expand our surgeon user base, and generated strong profitability.” Revenue was $221.172 million in 2026-Q3.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“These results reinforce our confidence in our procedure-focused strategy and the clinical value of our ecosystem.”
“Second Quarter 2026 Financial Results [TABLE] Quarter Ended June 30, 2026 || Total revenue | $214 million || GAAP gross margin | 72.2% || Non-GAAP gross margin | 72.5% || GAAP operating expenses | $1…”
The Company now expects adjusted EBITDA of approximately $137 million, reflecting continued year-over-year profitability expansion.
Stated in 2 of 3 supplied quarters. Management reported: “The Company also expects approximately $10 million of free cash flow for fiscal year 2026.” “The Company now expects adjusted EBITDA of approximately $140 million, an increase from its prior expectation of approximately $134 million, reflecting continued progress in operating leverage and margin expansion.”
“The Company now expects adjusted EBITDA of approximately $137 million, reflecting continued year-over-year profitability expansion.”
“The Company now expects adjusted EBITDA of approximately $140 million, an increase from its prior expectation of approximately $134 million, reflecting continued progress in operating leverage and ma…”
The Company also expects approximately $10 million of free cash flow for fiscal year 2026.
Stated in 2 of 3 supplied quarters. Management reported: “The Company also expects approximately $10 million of free cash flow for fiscal year 2026.” “The Company also continues to expect at least $20 million of free cash flow for fiscal year 2026.”
“The Company also expects approximately $10 million of free cash flow for fiscal year 2026.”
“The Company also continues to expect at least $20 million of free cash flow for fiscal year 2026.”
The new facility refinances the Company’s existing debt, including its prior term loan and asset-based lending facilities with Braidwell LP, Pharmakon Advisors LP, and MidCap Financial Trust, simplif…
Stated in 1 of 3 supplied quarters. Management reported: “At close, the facility carries an interest rate of SOFR plus 275 basis points and is expected to reduce interest expense by more than $6 million annually, with the potential to generate more than $35 million of savings over the life of the facility.” ““By lowering our cost of capital, extending our maturity profile, and partnering with a leading bank syndicate, we have strengthened our financial foundation.”
“The new facility refinances the Company’s existing debt, including its prior term loan and asset-based lending facilities with Braidwell LP, Pharmakon Advisors LP, and MidCap Financial Trust, simplif…”
Deliver the revised 2026 revenue outlook, including approximately $789 million of surgical revenue and $73 million of EOS revenue.
Over the trailing year it converted 0.37x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates (low R² over the window).
9 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-04.